On May 15, 2026, Octagon Capital Advisors disclosed a new stake in Xenon Pharmaceuticals (NASDAQ:XENE), acquiring 490,000 shares in a transaction estimated at $22.58 million based on quarterly average pricing.
What happened According to a filing with the Securities and Exchange Commission on May 15, 2026, Octagon Capital Advisors initiated a new position in Xenon Pharmaceuticals, buying 490,000 shares during the first quarter
The estimated transaction value was $22.58 million, based on the average closing price for the period. The stake ended the quarter valued at $28.49 million, reflecting price appreciation during the holding period. What else to know – This was a new position for Octagon, now accounting for 3.15% of the fund’s $903.61 million in reportable U.S. equity assets as of March 31, 2026. – Top holdings after the filing: – NASDAQ: DNTH: $163.36 million (18.1% of AUM) – NASDAQ: COGT: $90.45 million (10.0% of AUM) – NASDAQ: ABVX: $75.38 million (8.3% of AUM) – NASDAQ: ALMS: $62.36 million (6.9% of AUM) – NASDAQ: DFTX: $46.12 million (5.1% of AUM) – – As of May 14, 2026, shares of Xenon Pharmaceuticals were priced at $56.00, up 85% over the past year and outperforming the S&P 500 by roughly 60 percentage points.
Company overview Company snapshot – Xenon Pharmaceuticals develops clinical-stage therapeutics targeting neurological disorders, including epilepsy and encephalopathy, with a pipeline featuring XEN496, XEN1101, NBI-921352, and XEN007. – The firm operates a research-driven business model focused on advancing proprietary drug candidates through clinical development, leveraging strategic collaborations for select programs. – It serves patients with neurological disorders and is based in Canada. Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for neurological disorders. With a robust pipeline and strategic partnerships, the company is positioned to address significant unmet medical…